Skip to Main content Skip to Navigation
Journal articles

Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax

Abstract : Inhalational anthrax caused by Bacillus anthracis, a spore-forming Gram-positive bacterium, is a highly lethal infection. Antibodies targeting the protective antigen (PA) binding component of the toxins have recently been authorized as an adjunct to antibiotics, although no conclusive evidence demonstrates that anthrax antitoxin therapy has any significant benefit. We discuss here the rational basis of anti-PA development regarding the pathogenesis of the disease. We argue that inductive reasoning may induce therapeutic bias. We identified anthrax animal model analysis as another bias. Further studies are needed to assess the benefit of anti-PA antibodies in the treatment of inhalational anthrax, while a clearer consensus should be established around what evidence should be proven in an anthrax model.
Document type :
Journal articles
Complete list of metadata
Contributor : goossens pl goossens Connect in order to contact the contributor
Submitted on : Tuesday, July 20, 2021 - 5:52:23 PM
Last modification on : Thursday, April 7, 2022 - 10:10:46 AM
Long-term archiving on: : Thursday, October 21, 2021 - 7:03:22 PM


Publication funded by an institution


Distributed under a Creative Commons Attribution 4.0 International License




Jean-Nicolas Tournier, Clémence Rougeaux, Fabrice V. Biot, Pierre L. Goossens. Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax. MSphere, American Society for Microbiology., 2019, 4 (3), pp.e00282-19. ⟨10.1128/mSphere.00282-19⟩. ⟨pasteur-03293178⟩



Record views


Files downloads